US006001395A

United States Patent [19]

Coombes et al.

[11] **Patent Number: 6,001,395**

[45] **Date of Patent: Dec. 14, 1999**

[54] **POLYMERIC LAMELLAR SUBSTRATE PARTICLES FOR DRUG DELIVERY**

[75] Inventors: **Allan Gerald Arthur Coombes**; **Stanley Stewart Davis**, both of Nottingham; **Diane Lisa Major**, London; **John Michael Wood**, Hertsfordshire, all of United Kingdom

[73] Assignee: **Danbiosyst UK Limited**, Nottingham, United Kingdom

[21] Appl. No.: **08/983,156**

[22] PCT Filed: **Jul. 15, 1996**

[86] PCT No.: **PCT/GB96/01695**

§ 371 Date: **Mar. 30, 1998**

§ 102(e) Date: **Mar. 30, 1998**

[87] PCT Pub. No.: **WO97/02810**

PCT Pub. Date: **Jan. 30, 1997**

[30] **Foreign Application Priority Data**

Jul. 13, 1995 [GB] United Kingdom 9514285

[51] **Int. Cl.**[6] **A61K 9/16**; A61K 47/34

[52] **U.S. Cl.** **424/501**; 424/426; 424/490

[58] **Field of Search** 424/486, 426, 424/458, 428, 459, 490, 501; 514/952; 428/402, 402.24; 427/2.14

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,492,720	1/1985	Mosier .
5,827,531	10/1998	Morrison et al. .
5,869,103	2/1999	Yeh et al. .

FOREIGN PATENT DOCUMENTS

WO 95/11010 A1	4/1995	WIPO .
WO 95/35097 A1	12/1995	WIPO .

OTHER PUBLICATIONS

Alpar, et al., "Identification of Some of the Physico–Chemical Characteristics of Microspheres which Influence the Induction of the Immune Response Following Mucosal Delivery," *Eur. J. Pharm. Biopharm.* 40(4):198–202 (1994).

Cohen, et al., "The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes," *Proc. Natl. Acad. Sci. USA* 88:10440–44 (1991).

Eldridge, et al., "Biodegradable Microspheres as a Vaccine Delivery System," *Mol. Immunol.* 28(3):287–94 (1991).

Esparza, et al., "Parameters affecting the immunogenicity of microencapsulated tetanus toxoid," *Vaccine* 10(10):714–20 (1992).

Gray, et al., "B–cell memory is short lived in the absence of antigen," *Nature* 336:70–73 (1988).

Kalb, et al., "General crystalliazation behavior of poly(L–lactic acid)," *Polymer* 21(6):607–12; ACS Abstract No. 93:240075 (1980).

Khan, et al., "Immunopotentiation and Delivery Systems for Antigens for Single–Step Immunization: Recent Trends and Progress," *Pharm. Res.* 11(1):2–11 (1994).

Kreuter, et al., "Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants," *Vaccine* 6(3):253–56 (1988).

O'Hagan, et al., "Biodegradable microparticles as controlled release antigen delivery systems," *Immunology* 73(2):239–42 (1991); ACS Abstract No. 115:56995 (1991).

(List continued on next page.)

Primary Examiner—Edward J. Webman

Attorney, Agent, or Firm—Arnall Golden & Gregory, LLP

[57] **ABSTRACT**

The invention provides a composition for delivery of an active agent comprising a plurality of lamellar particles of a biodegradable polymer which is at least in part crystalline, and an active agent adsorbed to at least most of the particles. Preferably the biodegradablepolymer is at least 5% by weight crystalline. Preferred biodegradable polymers are poly(L-lactide) (L.PLA) or copolymers or blends of L.PLA. The particles are especially useful for the immobilization of antigens or allergens for vaccines.

18 Claims, 4 Drawing Sheets